Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Panel Backs NPS Pharma’s Gattex But Questions Registry Plans

This article was originally published in The Pink Sheet Daily

Executive Summary

A post-approval registry for the short bowel syndrome drug needs to be rigorously designed and enroll a large proportion of patients in the orphan indication if it is to provide useful information about the drug’s long-term risks, members of FDA Gastrointestinal Drugs Advisory Committee said.


Related Content

NPS Looks To Repeat Success At FDA AdCom With Second Orphan Drug
NPS Pharma’s REMS For Gattex Will Face FDA Panel Scrutiny


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts